Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 11/2019

Open Access 01-11-2019 | Gallbladder Cancer | Original Article – Cancer Research

Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer

Authors: Nicole Golob-Schwarzl, Christina Wodlej, Florian Kleinegger, Margit Gogg-Kamerer, Anna Maria Birkl-Toeglhofer, Johannes Petzold, Ariane Aigelsreiter, Michael Thalhammer, Young Nyun Park, Johannes Haybaeck

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2019

Login to get access

Abstract

Background

Gallbladder cancer (GBC) is a rare neoplasia of the biliary tract with high mortality rates and poor prognosis. Signs and symptoms of GBC are not specific and often arise at late stage of disease. For this reason, diagnosis is typically made when the cancer is already in advanced stages, and prognosis for survival is less than 5 years in 90% of cases. Biomarkers to monitor disease progression and novel therapeutic alternative targets for these tumors are strongly required. Commonly, dysregulated protein synthesis contributes to carcinogenesis and cancer progression. In this case, protein synthesis directs translation of specific mRNAs, and, in turn, promotes cell survival, invasion, angiogenesis, and metastasis of tumors. In eukaryotes, protein synthesis is regulated at its initiation, which is a rate-limiting step involving eukaryotic translation initiation factors (eIFs). We hypothesize that eIFs represent crossroads in the development of GBC, and might serve as potential biomarkers. The study focus was the role of eIF6 (an anti-association factor for the ribosomal subunits) in GBC.

Methods

In human GBC samples, the expression of eIF6 was analyzed biochemically at the protein (immunohistochemistry, immunoblot analyses) and mRNA levels (qRT-PCR).

Results

High levels of eIF6 correlated with shorter overall survival in biliary tract cancer (BTC) patients (n = 28). Immunohistochemical data from tissue microarrays (n = 114) demonstrated significantly higher expression levels of eIF6 in GBC compared to non-neoplastic tissue. Higher eIF6 expression on protein (immunoblot) and mRNA (qRT-PCR) level was confirmed by analyzing fresh frozen GBC patient samples (n = 14). Depletion of eIF6 (using specific siRNA-mediated knockdown) in Mz-ChA-2 and TFK-1 cell lines inhibited cell proliferation and induced apoptosis.

Conclusion

Our data indicates that eIF6 overexpression plays a major role in the translational control of GBC, and indicates its potential as a new biomarker and therapeutic target in GBC.
Appendix
Available only for authorised users
Literature
go back to reference Basu U, Si K, Warner JR, Maitra U (2001) The Saccharomyces cerevisiae TIF6 gene encoding translation initiation factor 6 is required for 60S ribosomal subunit biogenesis. Mol Cell Biol 21(5):1453–1462CrossRef Basu U, Si K, Warner JR, Maitra U (2001) The Saccharomyces cerevisiae TIF6 gene encoding translation initiation factor 6 is required for 60S ribosomal subunit biogenesis. Mol Cell Biol 21(5):1453–1462CrossRef
go back to reference Biffo S, Sanvito F, Costa S, Preve L, Pignatelli R, Spinardi L, Marchisio PC (1997) Isolation of a novel beta4 integrin-binding protein (p27 (BBP)) highly expressed in epithelial cells. J Biol Chem 272(48):30314–30321CrossRef Biffo S, Sanvito F, Costa S, Preve L, Pignatelli R, Spinardi L, Marchisio PC (1997) Isolation of a novel beta4 integrin-binding protein (p27 (BBP)) highly expressed in epithelial cells. J Biol Chem 272(48):30314–30321CrossRef
go back to reference Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RI, Liebhaber SA, Pasquinelli AE, Shiekhatter R (2007) MicroRNA silencing through RISC recruitment of eIF6. Nature 447(7146):823–828CrossRef Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RI, Liebhaber SA, Pasquinelli AE, Shiekhatter R (2007) MicroRNA silencing through RISC recruitment of eIF6. Nature 447(7146):823–828CrossRef
go back to reference Engelman JA (2009) Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562CrossRef Engelman JA (2009) Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562CrossRef
go back to reference Finch AJ, Hilcenko C, Basse N, Drynan LF, Goyenechea B, Menne TF, González Fernández A, Simpson P, D’Santos CS, Arends MJ, Donadieu J, Bellanné-Chantelot C, Costanzo M, Boone C, McKenzie AN, Freund SMV, Warren AJ (2011) Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman–Diamond syndrome. Genes Dev 25(9):917–929CrossRef Finch AJ, Hilcenko C, Basse N, Drynan LF, Goyenechea B, Menne TF, González Fernández A, Simpson P, D’Santos CS, Arends MJ, Donadieu J, Bellanné-Chantelot C, Costanzo M, Boone C, McKenzie AN, Freund SMV, Warren AJ (2011) Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman–Diamond syndrome. Genes Dev 25(9):917–929CrossRef
go back to reference Flavin RJ, Smyth PC, Finn SP, Laios A, O’toole SA, Barrett C, Ricciardi S, Brina D, Biffo S (2008) Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol 21(6):676–684CrossRef Flavin RJ, Smyth PC, Finn SP, Laios A, O’toole SA, Barrett C, Ricciardi S, Brina D, Biffo S (2008) Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol 21(6):676–684CrossRef
go back to reference Gantenbein N, Bernhart E, Anders I, Golob-Schwarzl N, Krassnig S, Wodlej C, Gogg-Kamerer M, Lindenmann J, Fink-Neuböck N, Brcic L, Gollowitsch F, Stacher-Priehse E, Rolff J, Hoffmann J, Silvestri A, Regenbrecht C, Reinhard C, Pehserl AM, Pichler M, Sokolova O, Naumann M, Mitterer V, Pertschy B, Bergler H, Popper H, Sattler W, Haybaeck J (2018) Eukaryotic translation initiation factor 6 impacts NSCLC. Eur J Cancer 101:165–180CrossRef Gantenbein N, Bernhart E, Anders I, Golob-Schwarzl N, Krassnig S, Wodlej C, Gogg-Kamerer M, Lindenmann J, Fink-Neuböck N, Brcic L, Gollowitsch F, Stacher-Priehse E, Rolff J, Hoffmann J, Silvestri A, Regenbrecht C, Reinhard C, Pehserl AM, Pichler M, Sokolova O, Naumann M, Mitterer V, Pertschy B, Bergler H, Popper H, Sattler W, Haybaeck J (2018) Eukaryotic translation initiation factor 6 impacts NSCLC. Eur J Cancer 101:165–180CrossRef
go back to reference García-Márquez A, Gijsbers A, de la Mora E, Sánchez-Puig N (2015a) Defective guanine nucleotide exchange in the Elongation Factor-Like 1 (EFL1) GTPase by mutations in the Shwachman-Diamond syndrome protein. J Biol Chem 290(29):17669–17678CrossRef García-Márquez A, Gijsbers A, de la Mora E, Sánchez-Puig N (2015a) Defective guanine nucleotide exchange in the Elongation Factor-Like 1 (EFL1) GTPase by mutations in the Shwachman-Diamond syndrome protein. J Biol Chem 290(29):17669–17678CrossRef
go back to reference García-Márquez A, Gijsbers A, de la Mora E, Sánchez-Puig N (2015b) Defective guanine nucleotide exchange in the Elongation Factor-Like 1 (EFL1) GTPase by mutations in the Shwachman-Diamond syndrome protein. J Biol Chem 290(29):17669–17678CrossRef García-Márquez A, Gijsbers A, de la Mora E, Sánchez-Puig N (2015b) Defective guanine nucleotide exchange in the Elongation Factor-Like 1 (EFL1) GTPase by mutations in the Shwachman-Diamond syndrome protein. J Biol Chem 290(29):17669–17678CrossRef
go back to reference Gartmann M, Blau M, Armache JP, Mielke T, Topf M, Beckmann R (2010) Mechanism of eIF6-mediated inhibition of ribosomal subunit joining. J Biol Chem 285(20):14848–14851CrossRef Gartmann M, Blau M, Armache JP, Mielke T, Topf M, Beckmann R (2010) Mechanism of eIF6-mediated inhibition of ribosomal subunit joining. J Biol Chem 285(20):14848–14851CrossRef
go back to reference Golob-Schwarzl N, Schweiger C, Koller C, Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofer AM, Wodlej C, Bergler H, Pertschy B, Uranitsch S, Holter M, El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Reinhard C, Regenbrecht C, Schicho R, Fickert P, Lax S, Haybaeck J (2017) Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. Oncotarget 8(60):101224–101243CrossRef Golob-Schwarzl N, Schweiger C, Koller C, Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofer AM, Wodlej C, Bergler H, Pertschy B, Uranitsch S, Holter M, El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Reinhard C, Regenbrecht C, Schicho R, Fickert P, Lax S, Haybaeck J (2017) Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. Oncotarget 8(60):101224–101243CrossRef
go back to reference Jackson RJ, Hellen CUT, Pestova TV (2010) The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 11(2):113–127CrossRef Jackson RJ, Hellen CUT, Pestova TV (2010) The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 11(2):113–127CrossRef
go back to reference Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC (2013) AKT/mTOR substrate P70S6 K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther 6:1373–1384PubMedPubMedCentral Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC (2013) AKT/mTOR substrate P70S6 K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther 6:1373–1384PubMedPubMedCentral
go back to reference Lin CJ, Malina A, Pelletier J (2009) c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. Cancer Res 69(19):7491–7494CrossRef Lin CJ, Malina A, Pelletier J (2009) c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. Cancer Res 69(19):7491–7494CrossRef
go back to reference Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644CrossRef Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644CrossRef
go back to reference Loreni F, Mancino M, Biffo S (2013) Translation factors and ribosomal proteins control tumor onset and progression: how? Oncogen 33:2145–2156CrossRef Loreni F, Mancino M, Biffo S (2013) Translation factors and ribosomal proteins control tumor onset and progression: how? Oncogen 33:2145–2156CrossRef
go back to reference Miluzio A, Beugnet A, Volta V, Biffo S (2009) Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation. EMBO Rep 10(5):459–465CrossRef Miluzio A, Beugnet A, Volta V, Biffo S (2009) Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation. EMBO Rep 10(5):459–465CrossRef
go back to reference Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A, Biffo S (2011a) Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell 19(6):765–775CrossRef Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A, Biffo S (2011a) Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell 19(6):765–775CrossRef
go back to reference Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A, Biffo S (2011b) Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell 19(6):765–775CrossRef Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A, Biffo S (2011b) Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell 19(6):765–775CrossRef
go back to reference Miluzio A, Oliveto S, Pesce E, Mutti L, Murer B, Grosso S, Ricciardi S, Brina D, Biffo S (2015a) Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo. Oncotarget 6(35):37471–37485CrossRef Miluzio A, Oliveto S, Pesce E, Mutti L, Murer B, Grosso S, Ricciardi S, Brina D, Biffo S (2015a) Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo. Oncotarget 6(35):37471–37485CrossRef
go back to reference Miluzio A, Oliveto S, Pesce E, Mutti L, Murer B, Grosso S, Ricciardi S, Brina D, Biffo S (2015b) Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo. Oncotarget 6(35):37471–37485CrossRef Miluzio A, Oliveto S, Pesce E, Mutti L, Murer B, Grosso S, Ricciardi S, Brina D, Biffo S (2015b) Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo. Oncotarget 6(35):37471–37485CrossRef
go back to reference Parsyan A (2014) Translation and its regulation in caner biology and medicine. Springer, Berlin (ISBN 978-94-017-9077-2) Parsyan A (2014) Translation and its regulation in caner biology and medicine. Springer, Berlin (ISBN 978-94-017-9077-2)
go back to reference Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC (2011) mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol 12(4):235–245CrossRef Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC (2011) mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol 12(4):235–245CrossRef
go back to reference Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L, Sonenberg N, Bitterman PB (1996) Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiological expressed or deregulated Myc. Mol Cell Biol 16(11):6573–6581CrossRef Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L, Sonenberg N, Bitterman PB (1996) Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiological expressed or deregulated Myc. Mol Cell Biol 16(11):6573–6581CrossRef
go back to reference Randi G, Franceschi S, La Vecchia C (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118(7):1591–1602CrossRef Randi G, Franceschi S, La Vecchia C (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118(7):1591–1602CrossRef
go back to reference Rosso P, Cortesina G, Sanvito F, Donadini A, Di Benedetto B, Biffo S, Marchisio PC (2004) Overexpression of p27BBP in head and neck carcinomas and their lymph node metastases. Head Neck 26(5):408–417CrossRef Rosso P, Cortesina G, Sanvito F, Donadini A, Di Benedetto B, Biffo S, Marchisio PC (2004) Overexpression of p27BBP in head and neck carcinomas and their lymph node metastases. Head Neck 26(5):408–417CrossRef
go back to reference Ruggero D (2009) The role of Myc-induced protein synthesis in cancer. Cancer Res 69(23):8839–8843CrossRef Ruggero D (2009) The role of Myc-induced protein synthesis in cancer. Cancer Res 69(23):8839–8843CrossRef
go back to reference Sanvito F, Piatti S, Villa A, Bossi M, Lucchini G, Marchisio PC, Biffo S (1999) The beta4 integrin interactor p27 (BBP/eIF6) is an essential nuclear matrix protein involved in 60S ribosomal subunit assembly. J Cell Biol 144(5):823–837CrossRef Sanvito F, Piatti S, Villa A, Bossi M, Lucchini G, Marchisio PC, Biffo S (1999) The beta4 integrin interactor p27 (BBP/eIF6) is an essential nuclear matrix protein involved in 60S ribosomal subunit assembly. J Cell Biol 144(5):823–837CrossRef
go back to reference Sanvito F, Vivoli F, Gambini S, Santambrogio G, Catena M, Viale E, Veglia F, Donadini A, Biffo S, Marchisio PC (2000) Expression of a Highly Conserved Protein, p27 BBP, during the Progression of Human Colorectal Cancer. Cancer Res 60(3):510–516PubMed Sanvito F, Vivoli F, Gambini S, Santambrogio G, Catena M, Viale E, Veglia F, Donadini A, Biffo S, Marchisio PC (2000) Expression of a Highly Conserved Protein, p27 BBP, during the Progression of Human Colorectal Cancer. Cancer Res 60(3):510–516PubMed
go back to reference Shaffer EA (2008) Gallbladder cancer: the basic. Gastroenterol Hepatol 4(1):737–741 Shaffer EA (2008) Gallbladder cancer: the basic. Gastroenterol Hepatol 4(1):737–741
go back to reference Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A (2017) Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol 23(22):3978–3998CrossRef Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A (2017) Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol 23(22):3978–3998CrossRef
go back to reference Siddiqui N, Sonenberg N (2015) Signaling to eIF4E in cancer. Biochem Soc Trans 43(5):763–772CrossRef Siddiqui N, Sonenberg N (2015) Signaling to eIF4E in cancer. Biochem Soc Trans 43(5):763–772CrossRef
go back to reference Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10(4):254–266CrossRef Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10(4):254–266CrossRef
go back to reference Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136(4):731–745CrossRef Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136(4):731–745CrossRef
go back to reference Spilka R, Ernst C, Kuldeep Mehta A, Haybaeck J (2013) Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett 340(1):9–21CrossRef Spilka R, Ernst C, Kuldeep Mehta A, Haybaeck J (2013) Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett 340(1):9–21CrossRef
go back to reference Wang XL, Cai HP, Ge JH, Su XF (2012) Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol 18(20):2540–2544CrossRef Wang XL, Cai HP, Ge JH, Su XF (2012) Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol 18(20):2540–2544CrossRef
go back to reference Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332–337CrossRef Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332–337CrossRef
go back to reference Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, Thomas M, Vasquez KM, DiGiovanni J (2007) Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 67(8):3794–3800CrossRef Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, Thomas M, Vasquez KM, DiGiovanni J (2007) Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 67(8):3794–3800CrossRef
go back to reference Zhang F, Xiang S, Cao Y, Li M, Ma Q, Liang H, Li H, Ye Y, Zhang Y, Jiang L, Hu Y, Zhou J, Wang X, Zhang Y, Nie L, Liang X, Gong W, Liu Y (2017) EIF3D promotes gallbladder cancer development by stabilizing GRK2 kinase and activating PI3 K-AKT signaling pathway. Cell Death Dis 8(6):e2868CrossRef Zhang F, Xiang S, Cao Y, Li M, Ma Q, Liang H, Li H, Ye Y, Zhang Y, Jiang L, Hu Y, Zhou J, Wang X, Zhang Y, Nie L, Liang X, Gong W, Liu Y (2017) EIF3D promotes gallbladder cancer development by stabilizing GRK2 kinase and activating PI3 K-AKT signaling pathway. Cell Death Dis 8(6):e2868CrossRef
go back to reference Zhu W, Li GX, Chen HL, Liu XY (2017) The role of eukaryotic translation initiation factor 6 in tumors. Oncol Lett 14(1):3–9CrossRef Zhu W, Li GX, Chen HL, Liu XY (2017) The role of eukaryotic translation initiation factor 6 in tumors. Oncol Lett 14(1):3–9CrossRef
Metadata
Title
Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer
Authors
Nicole Golob-Schwarzl
Christina Wodlej
Florian Kleinegger
Margit Gogg-Kamerer
Anna Maria Birkl-Toeglhofer
Johannes Petzold
Ariane Aigelsreiter
Michael Thalhammer
Young Nyun Park
Johannes Haybaeck
Publication date
01-11-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 11/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-03030-x

Other articles of this Issue 11/2019

Journal of Cancer Research and Clinical Oncology 11/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.